AT119040T - Central cholecystokinin antagonists for the treatment of psychiatric diseases. - Google Patents

Central cholecystokinin antagonists for the treatment of psychiatric diseases.

Info

Publication number
AT119040T
AT119040T AT90114993T AT90114993T AT119040T AT 119040 T AT119040 T AT 119040T AT 90114993 T AT90114993 T AT 90114993T AT 90114993 T AT90114993 T AT 90114993T AT 119040 T AT119040 T AT 119040T
Authority
AT
Austria
Prior art keywords
treatment
psychiatric diseases
cholecystokinin antagonists
central
central cholecystokinin
Prior art date
Application number
AT90114993T
Other languages
German (de)
Inventor
David Christopher Horwell
John Hughes
Geoff Neil Woodruff
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US38966589A priority Critical
Priority to US42189689A priority
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AT119040T publication Critical patent/AT119040T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27012795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT119040(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
AT90114993T 1989-08-04 1990-08-03 Central cholecystokinin antagonists for the treatment of psychiatric diseases. AT119040T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US38966589A true 1989-08-04 1989-08-04
US42189689A true 1989-10-16 1989-10-16

Publications (1)

Publication Number Publication Date
AT119040T true AT119040T (en) 1995-03-15

Family

ID=27012795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90114993T AT119040T (en) 1989-08-04 1990-08-03 Central cholecystokinin antagonists for the treatment of psychiatric diseases.

Country Status (9)

Country Link
US (1) US5550126A (en)
EP (2) EP0411668B2 (en)
JP (1) JPH0374328A (en)
AT (1) AT119040T (en)
CY (1) CY1983A (en)
DE (2) DE69017302D1 (en)
DK (1) DK0411668T4 (en)
HK (1) HK8197A (en)
LV (1) LV11431B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69017302D1 (en) * 1989-08-04 1995-04-06 Merck Sharp & Dohme Central cholecystokinin antagonists to treat psychiatric diseases.
US5324726A (en) * 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
US5399565A (en) * 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
US5206238A (en) * 1990-11-13 1993-04-27 Merck & Co., Inc. Cholecystokinin antagonists
US5220018A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5218115A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5218114A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
EP0518484A3 (en) * 1991-05-14 1993-03-17 Merck & Co. Inc. 1,4-benzodiazepines condesed with 5- and 6-membered heterocyclic rings to treat anxiety, pain, pupil constriction, withdrawal-syndrome or oncologic disorders
US5185331A (en) * 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
US5206237A (en) * 1991-05-14 1993-04-27 Merck & Co., Inc. Benzodiazepine analogs
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
EP0517412A1 (en) * 1991-06-03 1992-12-09 MERCK SHARP & DOHME LTD. Pharmaceutical formulations of a benzodiazepine
US5177071A (en) * 1991-06-17 1993-01-05 Merck & Co., Inc. 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
US5153191A (en) * 1991-08-20 1992-10-06 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
WO1993012791A1 (en) * 1991-12-20 1993-07-08 Merck Sharp & Dohme Limited Central cholecystokinin antagonists having pharmaceutical activity
IT1263116B (en) * 1992-04-09 1996-07-30 Rotta Research Lab Basic derivatives of glutamic acid and aspartic acid, process for their preparation and their pharmaceutical use
WO1993021499A1 (en) * 1992-04-22 1993-10-28 Copal Company Limited Absolute encoder
US5360802A (en) * 1992-05-11 1994-11-01 Merck Sharpe & Dohme Ltd. Benzodiazepine derivatives, compositions containing them and their use in therapy
US5378838A (en) * 1993-01-13 1995-01-03 Merck & Co., Inc. Benzodiazepine cholecystokinin antagonists
US5852010A (en) * 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5929071A (en) * 1996-07-02 1999-07-27 Merck & Co., Inc. Method for the treatment of preterm labor
AU3591697A (en) * 1996-07-02 1998-01-21 Merck & Co., Inc. Method for the treatment of preterm labor
AU9019198A (en) 1997-08-19 1999-03-08 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
JP4615727B2 (en) * 1998-12-24 2011-01-19 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Succinoylaminobenzodiazepine as an inhibitor of Aβ protein production
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
EP1183242A2 (en) 1999-05-26 2002-03-06 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
US6960576B2 (en) * 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
EP1222176A1 (en) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
JP2004508289A (en) 2000-04-03 2004-03-18 デュポン ファーマシューティカルズ カンパニー Cyclic lactams as inhibitors of Aβ protein production
IL151576D0 (en) * 2000-04-03 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic lactams as inhibitors of a-beta protein production
US20100009966A1 (en) * 2001-04-11 2010-01-14 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of abeta protein production
AU5700601A (en) * 2000-04-11 2001-10-23 Du Pont Pharm Co Substituted lactams as inhibitors of abeta protein production
AU6172801A (en) * 2000-05-17 2001-11-26 Du Pont Pharm Co Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
US6509333B2 (en) * 2000-06-01 2003-01-21 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of Aβ protein production
US20040043990A1 (en) * 2002-04-09 2004-03-04 Karen Jackson Method of treatment
US6713470B2 (en) * 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment
US20030139396A1 (en) * 2002-01-22 2003-07-24 Karen Gibson Method of treatment
US20040167146A1 (en) * 2002-01-22 2004-08-26 Karen Jackson Method of treatment
KR101155335B1 (en) * 2005-01-07 2012-06-11 엘지전자 주식회사 Multimedia message service operating method for mobile communication terminal
CN104059071B (en) 2006-07-10 2016-06-22 Paion英国有限公司 Fugitive benzodiazepine * salt and polymorphic thereof
JP2010526825A (en) * 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and their use to block reuptake of norepinephrine, dopamine and serotonin
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc The bromodomain inhibitors and uses thereof
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (en) 2012-06-06 2017-10-21 星宿藥物公司 Bromodomain inhibitors and uses thereof
AR094963A1 (en) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Excellent oxidation reaction conversion rate
ES2725928T3 (en) 2014-06-20 2019-09-30 Constellation Pharmaceuticals Inc Crystal forms of 2 - ((4S) -6- (4-chlorophenyl) -1-methyl-4H-benzo [c] isoxazolo [4,5-e] azepin-4-yl) acetamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE57892B1 (en) * 1984-06-25 1993-05-05 Rotta Research Lab Glutamic and aspartic acid derivatives
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US5004741A (en) * 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
CA1332410C (en) * 1984-06-26 1994-10-11 Roger M. Freidinger Benzodiazepine analogs
IT1215169B (en) * 1985-12-17 1990-01-31 Rotta Research Lab Alkyl oxygenated derivatives of glutamic and aspartic acids to antagonist activity of bioactive polypeptides and process for their preparation
IT1217123B (en) * 1987-02-05 1990-03-14 Rotta Research Lab optically active derivatives of 5-pentylamino acid 5-oxo pentanoic acid r to antagonist activity of cholecystokinin and process for their preparation
DE69017302D1 (en) * 1989-08-04 1995-04-06 Merck Sharp & Dohme Central cholecystokinin antagonists to treat psychiatric diseases.
US5153191A (en) * 1991-08-20 1992-10-06 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression

Also Published As

Publication number Publication date
EP0411668A3 (en) 1992-01-29
HK8197A (en) 1997-01-24
CY1983A (en) 1997-09-05
JPH0374328A (en) 1991-03-28
EP0411668B1 (en) 1995-03-01
DE69017302D1 (en) 1995-04-06
EP0727215A3 (en) 1996-11-06
DK0411668T4 (en) 1999-08-09
EP0411668A2 (en) 1991-02-06
US5550126A (en) 1996-08-27
LV11431B (en) 1996-12-20
LV11431A (en) 1996-08-20
DE69017302T3 (en) 1999-08-05
DK0411668T3 (en) 1995-03-27
DE69017302T2 (en) 1995-09-28
EP0411668B2 (en) 1998-11-11
EP0727215A2 (en) 1996-08-21

Similar Documents

Publication Publication Date Title
DE10199020I1 (en) Galanthamine or its analogues for the treatment of Alzheimer's disease
DE69016755D1 (en) Pharmaceutical sustained-release formulation for the treatment of periodontal disease.
DE69023748D1 (en) Use of nitrogen-containing macrocycles for the treatment of retroviral infections.
DE69002905D1 (en) A process for the preparation of lipidic microparticles.
DE68913638D1 (en) Treatment of aqueous systems.
DE69411424D1 (en) For treating diseases of the central nervous system usable benzimidazoles
DE3580518D1 (en) Geraet for treatment neurovegetative disorders.
DE3779346D1 (en) Composition for treating the skin.
DE69321030T2 (en) Means for stimulation of the heart
DE69200675T2 (en) Use of droloxifene for the treatment of bone diseases.
DE69013771T2 (en) Dental inserts in the treatment of periodontal disease.
AT89755T (en) The transdermal application of medicaments.
AT132366T (en) Composition for the treatment of dry eye disorders
DE69118325D1 (en) Device for prevention of cardiac dysfunction
DE58909465D1 (en) Arrangement for treatment of sinusitis.
DE69012124T2 (en) Improvements in the treatment of teeth.
DE59106042D1 (en) Device for enclosing the fixation of the extremities.
DE3874813T2 (en) Composition for treating the skin.
DE69422306D1 (en) Substituted pyrazolyl-benzenesulfonamides for the treatment of inflammation
MA21682A1 (en) Process for the preparation of therapeutic agents derived from quainclidine.
DE69327582D1 (en) Methods for the treatment of interleukin-1 and - tumor - necrosis - factor - related diseases
ATA907182A (en) Means for treatment of blutgefaessen or the like.
DE3873800T2 (en) Compositions for treatment of hypercholesterolemia.
DE68902649T2 (en) Locally applicable pharmaceutical preparation for treatment of entzuendungserkrankungen.
DE69329559D1 (en) Using mannosephosphaten for the treatment of fibrotic disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee